NOVARTIS FDA Approval NDA 021588

NDA 021588

NOVARTIS

FDA Drug Application

Application #021588

Documents

Letter2003-06-08
Letter2003-12-22
Letter2005-05-20
Letter2005-10-25
Letter2006-11-06
Letter2006-06-02
Letter2006-10-23
Letter2006-10-23
Letter2006-10-23
Letter2008-10-01
Letter2008-05-05
Letter2008-12-29
Letter2009-06-02
Letter2011-04-06
Letter2012-02-03
Letter2013-01-30
Letter2013-02-25
Letter2013-10-31
Letter2014-05-22
Label2003-04-28
Label2003-05-20
Label2003-12-08
Label2005-03-18
Label2005-10-25
Label2006-10-23
Label2006-10-23
Label2006-10-23
Label2006-09-28
Label2009-06-05
Label2012-01-31
Label2015-02-03
Review2015-05-26
Review2006-10-19
Review2006-10-19
Letter2003-05-29
Letter2004-06-25
Letter2005-03-18
Letter2005-05-20
Letter2006-10-23
Letter2006-10-02
Letter2006-10-23
Letter2007-09-25
Letter2008-10-01
Letter2008-10-01
Letter2009-06-02
Letter2009-02-13
Letter2011-04-06
Letter2015-02-02
Label2004-06-25
Label2006-11-06
Label2006-06-01
Label2006-10-23
Label2006-10-23
Label2007-09-19
Label2008-09-26
Label2008-09-26
Label2008-09-26
Label2009-02-12
Label2011-04-01
Label2011-04-01
Label2013-01-30
Label2013-02-26
Label2013-10-31
Label2014-05-28
Review2006-06-07
Review2004-08-09
Review2005-04-08
Review2006-10-19
Review2006-10-19
Review2006-10-19
Other Important Information from FDA2003-12-09
Letter2016-08-25
Letter2016-08-25
Label2016-08-25
Label2016-08-25
Label2016-09-29
Letter2016-10-04
Label2017-04-25
Letter2017-04-27
Label2017-09-07
Letter2017-09-08
Label2017-10-03
Letter2017-10-03
Pediatric Medical Review1900-01-01
Pediatric Written Request1900-01-01
Pediatric Clinical Pharmacology Review1900-01-01
Pediatric Statistical Review1900-01-01
Label2018-08-22
Letter2018-08-24
Letter2020-08-11
Letter2020-08-11
Label2020-08-11
Label2020-08-11
Label2022-03-25
Letter2022-08-22
Label2022-08-22

Application Sponsors

NDA 021588NOVARTIS

Marketing Status

Prescription001
Prescription002

Application Products

001TABLET;ORALEQ 100MG BASE1GLEEVECIMATINIB MESYLATE
002TABLET;ORALEQ 400MG BASE1GLEEVECIMATINIB MESYLATE

FDA Submissions

TYPE 3; Type 3 - New Dosage FormORIG1AP2003-04-18PRIORITY
EFFICACY; EfficacySUPPL2AP2003-12-08STANDARD
LABELING; LabelingSUPPL3AP2004-06-23STANDARD
EFFICACY; EfficacySUPPL5AP2005-03-14UNKNOWN
MANUF (CMC); Manufacturing (CMC)SUPPL6AP2005-05-19
LABELING; LabelingSUPPL7AP2005-05-18STANDARD
EFFICACY; EfficacySUPPL8AP2005-10-20UNKNOWN
LABELING; LabelingSUPPL9AP2006-10-30STANDARD
LABELING; LabelingSUPPL10AP2006-05-31STANDARD
EFFICACY; EfficacySUPPL11AP2006-10-19STANDARD
EFFICACY; EfficacySUPPL12AP2006-10-19STANDARD
EFFICACY; EfficacySUPPL13AP2006-10-19STANDARD
EFFICACY; EfficacySUPPL14AP2006-10-19UNKNOWN
EFFICACY; EfficacySUPPL16AP2006-09-27PRIORITY
EFFICACY; EfficacySUPPL17AP2006-10-19UNKNOWN
EFFICACY; EfficacySUPPL20AP2007-09-13UNKNOWN
LABELING; LabelingSUPPL21AP2008-09-26STANDARD
LABELING; LabelingSUPPL22AP2008-09-26STANDARD
MANUF (CMC); Manufacturing (CMC)SUPPL23AP2008-04-30N/A
EFFICACY; EfficacySUPPL24AP2008-09-26STANDARD
EFFICACY; EfficacySUPPL25AP2008-12-19PRIORITY
EFFICACY; EfficacySUPPL26AP2009-05-27STANDARD
LABELING; LabelingSUPPL27AP2009-02-10STANDARD
LABELING; LabelingSUPPL28AP2009-05-27STANDARD
EFFICACY; EfficacySUPPL30AP2011-04-01STANDARD
LABELING; LabelingSUPPL31AP2011-04-01STANDARD
EFFICACY; EfficacySUPPL35AP2012-01-31PRIORITY
EFFICACY; EfficacySUPPL37AP2013-01-25PRIORITY
LABELING; LabelingSUPPL38AP2013-02-21STANDARD
LABELING; LabelingSUPPL39AP2013-10-30STANDARD
LABELING; LabelingSUPPL40AP2014-05-22STANDARD
EFFICACY; EfficacySUPPL42AP2015-01-30STANDARD
EFFICACY; EfficacySUPPL45AP2016-08-25STANDARD
LABELING; LabelingSUPPL46AP2016-08-25STANDARD
LABELING; LabelingSUPPL47AP2016-09-27STANDARD
LABELING; LabelingSUPPL49AP2017-04-24STANDARD
LABELING; LabelingSUPPL51AP2017-09-06901 REQUIRED
LABELING; LabelingSUPPL52AP2017-09-29STANDARD
LABELING; LabelingSUPPL53AP2018-08-21STANDARD
LABELING; LabelingSUPPL56AP2020-08-10STANDARD
LABELING; LabelingSUPPL57AP2020-08-10STANDARD
LABELING; LabelingSUPPL60AP2022-03-24STANDARD
LABELING; LabelingSUPPL62AP2022-08-19STANDARD

Submissions Property Types

ORIG1Null25
SUPPL6Null0
SUPPL11Null31
SUPPL12Null31
SUPPL13Null31
SUPPL14Null31
SUPPL16Null26
SUPPL17Null31
SUPPL20Null41
SUPPL24Null6
SUPPL25Null6
SUPPL26Null6
SUPPL30Null6
SUPPL31Null6
SUPPL35Null6
SUPPL37Null6
SUPPL38Null6
SUPPL39Null6
SUPPL40Null7
SUPPL42Null6
SUPPL45Null6
SUPPL46Null15
SUPPL47Null6
SUPPL49Orphan5
SUPPL51Null15
SUPPL52Null6
SUPPL53Null7
SUPPL56Null15
SUPPL57Null6
SUPPL60Null15
SUPPL62Null7

TE Codes

001PrescriptionAB
002PrescriptionAB

CDER Filings

cder:Array
(
    [0] => Array
        (
            [ApplNo] => 21588
            [companyName] => 
            [docInserts] => ["",""]
            [products] => []
            [labels] => 
            [originalApprovals] => []
            [supplements] => 
            [actionDate] => 0000-00-00
        )

)

© 2026 FDA.report
This site is not affiliated with or endorsed by the FDA.